Abstract: The present- applicatien relates -to- an inhaler compns1ng essential- oil. Specifically, the present application relates to an inhaler comprising basil oil. The present., application also relates to an inhaler comprising basil oil _and another essential oil selected from a group of eucalyptus oil, cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender oil, fennel oil, ginger oil, orange oil, palm oil, rose oil, · lemon grass oil, garlic oil, anise oil and a mixture thereof. The present application specifically relates to an inhaler consisting essentially of a mixture of basil· oil and · eucalyptus oil. The inhaler of the present application comprising basil oil is useful for treating infection.
One embodiment of the present application relates to an inhaler comprising
essential oil. Another embodiment of the present application relates to an inhaler
consisting essentially of basil oil. Still another embodiment of the present application
relates to an inhaler comprising basil oil and another essential oil selected from a
group of eucalyptus oil, cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender
oil, fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon grass oil, garlic oil, anise
oil and a mixture thereof. Yet another embodiment of the present application relates
to an inhaler comprising basil oil which is useful for treating infection.
BACKGROUND
An inhaler is a device which is used for the delivery of medicine directly to the
lungs and airways.
CN 111202780A discloses an inhaler comprising 1-10 parts by weight of
orange peel essential oil, 10-20 parts by weight dried orange peel alcohol extract,
30-80 parts by weight of base liquid and 0.1-5 parts by weight of plant essential oil. It
is mentioned 'that the inhaler is useful for removing the nasal obstruction during cold
and cough.
W02020030566A 1 teaches an inhaler comprising 95.00 to 99.99% preferably
98. to 99.90% w/w of eucalyptus and 0.10 to 0.20% preferably 0.12 to 0.18% w/w of
camphor for treatment of upper respiratory tract infection.
U S20 1 00196521 A 1 discloses a method of treatment of hypoxia and related
disorders comprising administering an effective amount of a plant extract
formulation, wherein said formulation comprising a mixture of: a) lemon oil; b)
eucalyptus oil; c) basil oil; d) davana oil; e) rosewood oil; f) fennel oil; and g)
citronella oil.
Vicks inhaler, marketed by Proctor and Gamble, is used for relief of nasal
congestion associated with allergic and infectious upper respiratory tract disorders. It
contains a mixture of menthol, camphor and Siberian . pine needle oil as active
iflgredients. Although Vicks inhaler is a very popular product, it does not treat the
infection, it only helps relieving the symptoms of the infection.
Teles Andrade et al., Journal of Essential Oil Research, 26:1, 34-40, (001:
10.1080/1 0412905.2013.860409) discloses anti-microbial property of different
nEa u-r n .a_ 'I 11 _ ·-,n·"'ln. 1 "l' • n 11
.., ~ssehfral OilS' against 'l'ia'rious mi'er~o~~~~s.
.-, n ·""') ·~ i · "-" """
U T n. ..-a - .".'. ..,'~ ·- .... '"' ""' ""' .... n.t::! .....,-. 2 ?-1-G.-'-'ii..L.
-Q)
C)
Ill
D..
Q) -1-- N
E....
0
-LL. .....
0'"" '""
CIO
-::!"
0 ..........
0
N
0
~.....
M
.-.:.:!.". -.......... 0
oN Tnn
N .do II 'ltJ'
I > z0 T·nn
I ..,g,..ii .,..;
-::!"
0
Though there are many inhalers known in the prior art for treatment of upper
respiratory tract infection and providing relief of nasal congestion, there is a need in
the art for an inhaler which is more effective in treating infection of nasal cavity,
upper respiratory tract and airways by delivering essential oils into the site of
infection so that it can be cured without any side effects.
SUMMARY OF THE INVENTION
First embodiment of the present application relates to an inhaler comprising
essential oil.
Second embodiment of the present application relates to an inhaler
comprising basil oil.
Third embodiment of the present application relates to an inhaler comprising
basil oil which useful for treating infection.
Fourth embodiment of the present application relates to an inhaler comprising
a mixture of basil oil and another essential oil.
In one aspect, another essential oil may be selected from a group of·
eu~alyptus oil, cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender oil,
fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil
and a mixture thereof.
Fifth embodiment of the present application relates to an inhaler consisting
essentially of basil oil.
Sixth embodiment of the present application relates· to an inhaler consisting
essentially of a mixture of basil oil and eucalyptus oil.
'
Seventh embodiment of the present application relates to an inhaler
consisting essentially of a mixture of basil oil and another essential oil.
In one aspect, another essential oil may be selected from a group of
eucalyptus oil, cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender oil,
fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil
and a mixture thereof.
One embodiment of the present application relates to an inhaler comprising a
mixture of basil oil and eucalyptus oil.
Still another embodiment of the present application relates to a mixture of
~-y·n1
Jbl "'\od'"..i..
3
-Q)
C)
Ill
D..
Q) -1-- N
E....
0
-LL. .....
"0" '"
CIO
-::1'
0 ..........
0
N
0
~.....
M
.-.::.1..' -.......... 0
O
N TIM £"1.
...1}:, ll 'lt.ofl'
~
> z0 TMi"'I ..d::o II ""''
-::1'
0
Yet another embodiment of the present application relates to a mixture of
basil oil and clove oil.
Another embodiment of the present application relates to a mixture of basil oil
and tea tree oil.
Still another embodiment of the present application relates to a mixture of
basil oil and black pepper oil.
Yet another embodiment of the present application relates to a mixture· of
basil oil and lavender oil.
Another embodiment of the present application relates to a mixture of basil oil
and fennel oil.
Still another black embodiment of the present application relates to a mixture
of basil oil and ginger oil.
Yet another embodiment of the present application relates to a mixture of
qasil oil and or~nge oil.
Another embodiment of the present application relates to a mixture of basil oil
· and palm oil.
Still another embodiment of the present application relates to a mixture of
basil oil and rose oil.
Yet another embodiment of the present application relates to a mixture of
basil oil and lemon grass oil.
Another embodiment of the present application relates to a mixture of basil oil
and garlic oil.
Yet another embodiment of the present application relates to a mixture of
basil oil and anise oil.
Still another embodiment of the present application relates to a mixture of
ba?il oil, eucalyptus oil and another essential oil selected from a group of cinnamon
oil, clove oil, tea tree oil, black pepper oil, lavender oil, fennel oil, ginger oil, orange
oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil and a mixture thereof.
DETAILED DESCRIPTION OF THE INVENTION
-
Inhaler is an effective device for delivering medicinal products directly into the
nasal cavity, lungs, upper respiratory tract and airways. The present application
relates to an inhaler which is useful for treating infection of nasal cavity, lungs, upper
n. I!:: 1 u. T n. ill· _ 1 11 _ ·--:. n. ·• n. 1 '7 • n 1
... 're'spiratory 1'ract -and._ ai'rtvays .... I he present application· specifically relates to an
1 ""W·nn
11 ·•n·•n .. ...;....,;,.
n~tuT nn-~~-h...;..~~ ~·
fj,i:: t- I I ,d:.. 'loJ '"""'0. 4
-Q)
C)
Ill
D..
Q) -1-- N
E....
0
-LL. .....
0"" '"
CIO
-::1'
0 ..........
0
N
0
~.....
M
.-:.:.1..' -.......... 0
~ Tn.n.
~ ...II. D ;J
> 0 z I
-::1'
0
ihhaler comprising essential oil which is useful for delivering the essential oil directly
into the nasal cavity·, lungs, upper respiratory tract and airways to treat infection.
Since the essential oil is also soothing and refreshing; does not cause irritation like a
decongestant e.g. Vicks Inhaler, the inhaler of the present application serves dual
purposes of treating infection as well as providing relief to the patient.
First embodiment of the present application relates to an inhaler comprising
essential oil.
Second embodiment of the present application relates to an inhaler
comprising basil oil.
Third embodiment of the present application relates to an inhaler comprising
qasil oil which useful for treating infection.
Fourth embodiment of the present application relates to an inhaler comprising
a mixture of basil oil and another essential oil.
In one aspect, another essential oil may be selected from a group of
eucalyptus oil, cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender oil,
fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil
and a mixture thereof.
Fifth embodiment of the present application relates to an inhaler consisting
essentially of basil oil.
Sixth embodiment of the present application relates to an inhaler consisting
essentially of a mixture of basil oil and eucalyptus oil.
Seventh embodiment of the present application relates to an inhaler
consisting essentially of a mixture of basil oil and another essential oil.
In one aspect, another essential oil may be selected from a group of
eucalyptus oil, cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender oil,
fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil
and a mixture thereof. ·
One embodiment of the present application relates to an inhaler comprising a
mixture of basil oil and eucalyptus oil.
Still another embodiment of the present application relates to an inhaler
co~prising a mixture of basil oil and cinnamon oil.
Yet another embodiment of the present application relates to an inhaler
-Q)
C)
Ill
D..
Q) -1-- N
E....
0
-LL. .....
0"" '"
CIO
-::1'
0 ..........
0
N
0
-.N... .
M
.-:.:.1..' -.......... 0
/
Another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and tea tree oil.
Still another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and black pepper oil.
Yet another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and lavender oil.
Another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and fennel oil.
Still another black embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and ginger oil.
Yet another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and orange oil.
Another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and palm oil.
Still another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and rose oil.
Yet another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and lemon grass oil.
Another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and garlic oil.
Still another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil and anise oil.
Yet another embodiment of the present application relates to an inhaler
comprising a mixture of basil oil, eucalyptus oil and another essential oil selected
from a group of cinnamon oil, clove oil, tea tree oil, black pepper oil, lavender oil,
fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil
and a mixture thereof .
One or more essential oils selected from a group of eucalyptus oil, cinnamon
oil, clove oil, tea tree oil, black pepper oil, lavender oil, fennel oil, ginger oil, orange
oil, palm oil, rose oil, lemon grass oil, garlic oil, anise oil and a mixture thereof may
be mixed with basil oil since all these essential oils are also reported to have antiinfective
effects. In combination with basil oil, the combination acts as a stronger
N T·n n n ;::· n: u T.· n: ill' _ "'1. ., _ ·-. n ., n 1. • • n 11
O..a..a""""'
~
>
· ..., ""'atfti-'irffectlve tht:lri" ba"sir Oil'-'alon~. Hent:e, the present application also relates to a
~ T r. n
I .,a.,.l 'W'
-::1'
0
--·~- .,..,.nn ,..:.0. - ....,_ "'t 1 . J: l.a :; •.. a "- "' • a "'\J n.c 1 u. ;. • ... " - ' · - -. ...., ""' ...., - • -
a..#J..f-!l:::t!!~oo 'itJ~ ..&.&. 6
-Q)
C)
Ill
D..
Q) -1-- N
E....
0
-LL. .....
0"" '"
CIO
-::1'
0 ..........
0
N
0
~.....
M
.-.::.1..' -.......... 0
~ -rn.n
N ...!. R ~
I > z0 T•.· n.n, I
-::1'
0
combination inhaler compnsmg basil oil and another essential oil which may be
selected from a group of eucalyptus oil, .cinnamon oil, clove oil, tea tree oil, black
pepper oil, lavender oil, fennel oil, ginger oil, orange oil, palm oil, rose oil, lemon
grass oil, garlic oil, anise oil and a mixture thereof. Specifically, the present
application also relates to a combination inhaler comprising basil oil and eucalyptus
oil. More specifically, the present application also relates to a combination inhaler
consisting essentially of basil oil and eucalyptus oil.
Basil oil is a type of essential oil commonly used in aromatherapy. It is
sourced from Ocimum basilicum or Ocimum sanctum plant. Basil oil is used for
treating cold and cough and also for treating infection. In addition, basil oil is used to
enhance mood and decrease fatigue of an individual.
Therefore, it was thought of treating infection of nasal cavity, upper respiratory
Tract, lungs and airways by delivering basil oil through an inhaler. It will not only
provide treatment to the patient but also enhance the mood and decrease fatigue of
t~e patient. Since the basil oil through an inhaler will be delivered directly to the
ir~fected regions of nasal cavity, upper respiratory tract, lungs and airways, it will
provide immediate relief and fast treatment. Also, there will be no side effects
associated with basil oil administration.
Eucalyptus oil is a type of essential oil which is commonly used. It is sourced
from Eucalyptus globulus plant. It is commonly used for relieving cough and joint
pam.
The inventor of the present application surprisingly found out that a mixture of
basil oil and eucalyptus oil when administered through the nasal cavity is capable of
treating infection of nasal cavity, lungs, upper respiratory tract and airways.
Moreover, the mixture of basil oil and eucalyptus oil enhances the mood and
decrease fatigue of the patient. Since the mixture of basil oil and eucalyptus oil
through an inhaler is delivered directly to the infected regions of nasal cavity, upper
respiratory tract, lungs and airways, it provides immediate relief and fast treatment.
Also, there will be no side effects associated with administration of a mixture of basil
oil and eucalyptus oil.
no::: 1 u T n.,., _ 1 1 _ ·~ n.·~ n 1 "'l" • n.;
i:Ji:....&. .. n!l . ...!.b ~""9i ..a.....!:< ~G.'\...J''='\:J ...&.: "llcJ'...i!r..
7
-Q)
C)
Ill
D..
Q) -1-- N
E....
0
-LL. .....
"0" '"
CIO
-::1'
0 ..........
0
N
0
~.....
M
.-:.:.1..' -.......... 0
N
0 TIn •'"'t
N ...n..ii :q,p>
I >
Zo =rno """. .., I
-::1'
0
The inhaler device used for the delivery of basil oil of the present application
may be any inhaler known in the art. Specifically, the inhaler device for the delivery
of basil oil of the present application may be the inhaler taught in the US patent
number, US3027897. In another aspect of the present application, the inhaler device
for the delivery of basil oil of the present application may be the inhaler taught in the
US patent number, US4694824. In yet another aspect of the present application, the
inhaler device for the delivery of basil oil of the present application may be the
inhaler taught in the US patent number, US1950926. In still another aspect of the
present application, the inhaler device for the delivery of basil oil of the present
application may be the inhaler taught in the US patent number, US4903850.
In another embodiment of the present application, the inhaler device may be a
nebulizer. In another embodiment of the present application, an inhaler comprises an
inhaler device or a nebulizer. The inhaler device used for the delivery of basil oil of
the present application may be any nebulizer in the art. Specifically, the inhaler
device for the delivery of basil oil of the present application may be the nebulizer
taught in the US patent number, US5054477. In another aspect of the present
application, the inhaler device for the delivery of basil oil of the present application
may be the nebulizer taught in the US patent number, LJS6994083.
Another embodiment of the present application also relates to a process for
preparation of the inhaler comprising essential oil, especially basil oil as the essential
oil. Basil oil may be applied to a cotton wick. If a combination of the essential oil, as
tt::~L:Jght in the present application, is used then essential oils may be combined in a
desired ratio and then applied on the cotton wick. Conventionally, this wick is
inserted on the support of the inhaler, which also comprises a nasal nozzle and a
cap.
When two essential oils are used for the preparation of the inhaler of the
present application, then the essential oils may be mixed in a ratio of about 1:1 to
about 1:10, specifically of about 1:5.
When more than two essential oils are mixed together, they can be mixed with
any ratio in such a way that one of the oils may be present in not less than 1% v/v of
n.~~::: a u T . n " _ 11 4!. _ '""'ll n ., n 11 ,. • n. 1 .... The 'total composition ......... ._..., .... ' . '-' ""'
-~ ........ ., n 11 .,. • .n ,--,
- ·- .• u. - n il - 11. 1. • •·. ..... • • ._.. '"" \1. li r.- G. It qJ- -'i --. ..&.- - lb. "-" £:,. ~
w~e.-e•·• 8
'.
'
. ,. ' . ·'
-Q)
C)
Ill
D..
Q) -1-- N
E...
0
-LL. .....
0"" ""
CIO
-::!"
0 ..........
0
N
0
~.....
·M
.-.:.:!.". -.......... 0
In one specific embodiment of the present application, the essential oil used in
the inhaler is a mixture of basil oil and eucalyptus oil. Basil oil and eucalyptus oil may
be mixed in a ratio of about 1:1 to about 1:10 for the inhaler of the present
application. Specifically, basil oil and eucalyptus oil may be mixed in a ratio of about
1 :5. More specifically, basil oil and eucalyptus oil may be mixed in a ratio of about
1 :4.
Certain specific aspects and embodiments of the present application will be
. '
explained in greater detail with reference to the following examples, which are
provided only for purposes of illustration and should not be construed as limiting the
scope of the disclosure in any manner.
EXAMPLE 1: Preparation of inhaler
Basil oil was extracted as known in the art from the leaves, flower and seeds of
Ocimum basi/icum plant. Eucalyptus oil was extracted as known in the art from the
leave~. flower and seeds of Eucalyptus globu/us plant. Basil oil and eucalyptus oil in
a ratio of 1 :4 was mixed together and was soaked with tight cotton pack. The cotton
pack, thus produced, was packed in an inhaler device .
l;xample 2: Preparation of inhaler
Basil oil was extracted as known in the art from the leaves, flower and seeds of
Ocimum basi/icum plant. Basil oil was soaked with tight cotton pack. The cotton
pack, thus produced, was packed in an inhaler device.
1/WE CLAIM:
1. An inhaler comprising basil oil.
2. The inhaler of claim 1, wh~rein the inhaler comprises a mixture of basil oil and
another essential oil;
wherein the other essential oil is selected from a group of eucalyptus oil, cinnamon
oil, clove oil, tea tree oil, black pepper oil, lavender oil, fennel oil, ginger oil, orange . .
oil, palm oil, rose oil, lemon grass oil, ginger oil, anise oil and a mixture thereof.
3. The inhaler of claim 1, wherein the inhaler comprises a mixture of basil oil and
eucalyptus oil.
4. An inhaler consisting essentially of basil oil.
5. An inhaler consisting essentially of a mixture of ba~il oil and another essential oil;
wherein the other essential oil is selected from a group of eucalyptus oil, cinnamon
oil, clove oil, tea tree oil, black pepper oil, lavender oil, fennel oil, ginger oil, orange
oil; palm oil, rose oil, lemon grass oil, ginger oil, anise oil and a mixture thereof.
6. An inhaler consisting essentially of a mixture of basil oil and eucalyptus oil.
| Section | Controller | Decision Date |
|---|---|---|
| section 15 | Manoj Gopalrao Somkuwar | 2023-09-20 |
| Section 77 | Manoj Gopalrao Somkuwar | 2025-03-26 |
| # | Name | Date |
|---|---|---|
| 1 | 202011048071-Correspondence to notify the Controller [09-01-2025(online)].pdf | 2025-01-09 |
| 1 | 202011048071-FORM-24 [20-11-2023(online)].pdf | 2023-11-20 |
| 1 | 202011048071-Other Patent Document-071220.pdf | 2021-10-19 |
| 2 | 202011048071-Other Patent Document-041120.pdf | 2021-10-19 |
| 2 | 202011048071-RELEVANT DOCUMENTS [20-11-2023(online)].pdf | 2023-11-20 |
| 2 | 202011048071-ReviewPetition-HearingNotice-(HearingDate-15-01-2025).pdf | 2024-12-27 |
| 3 | 202011048071-FORM-24 [20-11-2023(online)].pdf | 2023-11-20 |
| 3 | 202011048071-FORM-26 [21-10-2023(online)].pdf | 2023-10-21 |
| 3 | 202011048071-FORM28-071220.pdf | 2021-10-19 |
| 4 | 202011048071-RELEVANT DOCUMENTS [20-11-2023(online)].pdf | 2023-11-20 |
| 4 | 202011048071-FORM28-041120.pdf | 2021-10-19 |
| 4 | 202011048071-FORM 4 [19-10-2023(online)].pdf | 2023-10-19 |
| 5 | 202011048071-US(14)-HearingNotice-(HearingDate-04-09-2023).pdf | 2023-08-24 |
| 5 | 202011048071-FORM-26 [21-10-2023(online)].pdf | 2023-10-21 |
| 5 | 202011048071-Form 9-071220.pdf | 2021-10-19 |
| 6 | 202011048071-Form 5-041120.pdf | 2021-10-19 |
| 6 | 202011048071-FORM 4 [19-10-2023(online)].pdf | 2023-10-19 |
| 6 | 202011048071-Abstract-280322.pdf | 2022-03-29 |
| 7 | 202011048071-US(14)-HearingNotice-(HearingDate-04-09-2023).pdf | 2023-08-24 |
| 7 | 202011048071-Form 3-071220.pdf | 2021-10-19 |
| 7 | 202011048071-Claims-280322.pdf | 2022-03-29 |
| 8 | 202011048071-Abstract-280322.pdf | 2022-03-29 |
| 8 | 202011048071-FER Reply-280322.pdf | 2022-03-29 |
| 8 | 202011048071-Form 3-041120.pdf | 2021-10-19 |
| 9 | 202011048071-Claims-280322.pdf | 2022-03-29 |
| 9 | 202011048071-Form 2(Title Page)-041120.pdf | 2021-10-19 |
| 9 | 202011048071-Others-280322.pdf | 2022-03-29 |
| 10 | 202011048071-Abstract-160322.pdf | 2022-03-21 |
| 10 | 202011048071-FER Reply-280322.pdf | 2022-03-29 |
| 10 | 202011048071-Form 18-071220.pdf | 2021-10-19 |
| 11 | 202011048071-Claims-160322.pdf | 2022-03-21 |
| 11 | 202011048071-Form 1-041120.pdf | 2021-10-19 |
| 11 | 202011048071-Others-280322.pdf | 2022-03-29 |
| 12 | 202011048071-Abstract-160322.pdf | 2022-03-21 |
| 12 | 202011048071-FER Reply-160322.pdf | 2022-03-21 |
| 12 | 202011048071-FER.pdf | 2021-12-06 |
| 13 | 202011048071-Others-160322.pdf | 2022-03-21 |
| 13 | 202011048071-Claims-160322.pdf | 2022-03-21 |
| 14 | 202011048071-FER Reply-160322.pdf | 2022-03-21 |
| 14 | 202011048071-FER.pdf | 2021-12-06 |
| 15 | 202011048071-Claims-160322.pdf | 2022-03-21 |
| 15 | 202011048071-Form 1-041120.pdf | 2021-10-19 |
| 15 | 202011048071-Others-160322.pdf | 2022-03-21 |
| 16 | 202011048071-Abstract-160322.pdf | 2022-03-21 |
| 16 | 202011048071-FER.pdf | 2021-12-06 |
| 16 | 202011048071-Form 18-071220.pdf | 2021-10-19 |
| 17 | 202011048071-Others-280322.pdf | 2022-03-29 |
| 17 | 202011048071-Form 1-041120.pdf | 2021-10-19 |
| 17 | 202011048071-Form 2(Title Page)-041120.pdf | 2021-10-19 |
| 18 | 202011048071-Form 3-041120.pdf | 2021-10-19 |
| 18 | 202011048071-Form 18-071220.pdf | 2021-10-19 |
| 18 | 202011048071-FER Reply-280322.pdf | 2022-03-29 |
| 19 | 202011048071-Claims-280322.pdf | 2022-03-29 |
| 19 | 202011048071-Form 2(Title Page)-041120.pdf | 2021-10-19 |
| 19 | 202011048071-Form 3-071220.pdf | 2021-10-19 |
| 20 | 202011048071-Abstract-280322.pdf | 2022-03-29 |
| 20 | 202011048071-Form 3-041120.pdf | 2021-10-19 |
| 20 | 202011048071-Form 5-041120.pdf | 2021-10-19 |
| 21 | 202011048071-Form 3-071220.pdf | 2021-10-19 |
| 21 | 202011048071-Form 9-071220.pdf | 2021-10-19 |
| 21 | 202011048071-US(14)-HearingNotice-(HearingDate-04-09-2023).pdf | 2023-08-24 |
| 22 | 202011048071-FORM 4 [19-10-2023(online)].pdf | 2023-10-19 |
| 22 | 202011048071-Form 5-041120.pdf | 2021-10-19 |
| 22 | 202011048071-FORM28-041120.pdf | 2021-10-19 |
| 23 | 202011048071-Form 9-071220.pdf | 2021-10-19 |
| 23 | 202011048071-FORM-26 [21-10-2023(online)].pdf | 2023-10-21 |
| 23 | 202011048071-FORM28-071220.pdf | 2021-10-19 |
| 24 | 202011048071-FORM28-041120.pdf | 2021-10-19 |
| 24 | 202011048071-Other Patent Document-041120.pdf | 2021-10-19 |
| 24 | 202011048071-RELEVANT DOCUMENTS [20-11-2023(online)].pdf | 2023-11-20 |
| 25 | 202011048071-Other Patent Document-071220.pdf | 2021-10-19 |
| 25 | 202011048071-FORM28-071220.pdf | 2021-10-19 |
| 25 | 202011048071-FORM-24 [20-11-2023(online)].pdf | 2023-11-20 |
| 26 | 202011048071-ReviewPetition-HearingNotice-(HearingDate-15-01-2025).pdf | 2024-12-27 |
| 26 | 202011048071-Other Patent Document-041120.pdf | 2021-10-19 |
| 27 | 202011048071-Other Patent Document-071220.pdf | 2021-10-19 |
| 27 | 202011048071-Correspondence to notify the Controller [09-01-2025(online)].pdf | 2025-01-09 |
| 1 | 202011048071E_06-12-2021.pdf |
| 1 | tkdleucalyptusE_06-12-2021.pdf |
| 2 | tkdlbasilE_06-12-2021.pdf |
| 2 | tkdlbasiloilE_06-12-2021.pdf |
| 3 | tkdlbasilE_06-12-2021.pdf |
| 3 | tkdlbasiloilE_06-12-2021.pdf |
| 4 | 202011048071E_06-12-2021.pdf |
| 4 | tkdleucalyptusE_06-12-2021.pdf |